Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The new drug reduced HDV viral load and lowered liver enzyme levels in people with hepatitis B and D.
Stivarga also improved survival in those with recurrent HCC after a liver transplant.
Bulevirtide plus pegylated interferon shows promise for hard-to-treat coinfection.
Jeffrey V. Lazarus files a dispatch from Amsterdam, where the International Liver Congress is underway.
Those taking AbbVie’s combo therapy virus who reduced their dose of ribavirin because of side effects, saw no reduction in their cure rates.
Sofosbuvir and ribavirin cured participants with genotype 2 or 3 of hepatitis C virus at rates in the mid-70 percent range in two new Phase II...
AbbVie?s five-drug hepatitis C virus (HCV) combination therapy demonstrated cure rates in the mid-90 percent range when taken for as little as...
Hepatitis C therapy including daclatasvir, asunaprevir and BMS-791325 achieved a cure in up to 94 percent of treatment-naive people with genot...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.